Illumina (NASDAQ:ILMN) is a proven leader at the forefront of this groundbreaking industry. Scope and Methodology . Illumina has grown from just $10 million in revenues … @themotleyfool #stocks $ILMN $PACB, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Illumina Inc (ILMN) Q3 2020 Earnings Call Transcript, The 1 Stock Most Likely to Win From a Potentially Game-Changing Coronavirus Discovery, Copyright, Trademark and Patent Information. Our preliminary analysis suggests that these challenges are transitory and do not reflect a macro change to the fundamentals of our business," said Francis deSouza, president and CEO of Illumina. Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Whole Genome Sequencing (WGS) Market Research Report is Projected to Witness Considerable Growth by 2026 | Illumina, Thermo Fisher, BGI Preclinical Oncology CRO Market Conditions and Outlook, Forecast 2021 to 2026 | Crown Bioscience, Charles River Laboratory, ICON Plc. In the final quarter of 2019, Illumina's revenue totaled $953 million. Â. The growth is mainly due to the growing number of chronic diseases and government initiatives. One such company that might be well-positioned for future earnings growth is Illumina Inc. . GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Illumina also reported weakness in the direct-to-consumer market. On Jan. 13, Illumina announced that it was partnering with Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven oncology. For the full year, Illumina said it now expects revenue to grow about 6%. 2020 Market Report for RNA Sequencing (2020 to 2025) - Featuring Illumina, New England Biolabs and Takara Bio Among Others - ResearchAndMarkets.com December 15, 2020 04:37 AM Eastern Standard Time Global Business and Financial News, Stock Quotes, and Market Data and Analysis. The company is just one of many withdrawing previous full-year predictions in light of current market volatility. Data is a real-time snapshot *Data is delayed at least 15 minutes. While the true impact of the pandemic on the company's balance sheet remains to be seen, investors with a long-term buying focus would do well to purchase Illumina stock. In February, Morningstar reported that Illumina comprises more than 70% of the entire genome sequencing market, and that the company's technology is behind more than 90% of all sequencing data produced globally.Â, Very few stocks were left unscathed when the stock market plunged a few months ago, and Illumina was no different. All Rights Reserved. In fiscal 2019, Illumina's revenue rose by 6% on a year-over-year basis to roughly $3.5 billion. Illumina maintains that "... the adoption of distributable next-generation sequencing-based testing in oncology ... has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. Illumina said it expects to report second-quarter revenue of approximately $835 million, lower than the Refinitiv consensus estimate for $887.9 million in revenue. Rachel primarily covers healthcare stocks for the Fool. That's far below its previous projection for about 13% to 14% revenue growth in fiscal 2019. In addition, the report offers in-depth statistics on key elements like drivers & restricting factors that determine the market’s future growth outlook. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is Illumina Stock a Buy? Illumina said it now expects revenue to grow about 6% this fiscal year. Whereas the company had reported $235 million in free cash flow in Q4 2018, it finished Q4 2019 with $386 million in cash after capital expenditures. At the J.P. Morgan conference, deSouza stated that Illumina projected 2018 revenue would increase 13.5% from last year. GRAIL extends Illumina's portfolio … By 2027, it's projected to be worth $31.1 billion. Stock Advisor launched in February of 2002. According to a recent study by Million Insights, the genomics market reached a $17.2 billion valuation in 2019. This isn't all that surprising. Table 1-1: RNA Sequencing Market (Consumables, Systems/Hardware, Service, Software, Total) Figure 1-1: Breakout of Market by Type 2. Today, shares run at about $383 each. Illumina has stated it thinks the addressable market, NGS (next generation sequencing) oncology, will grow to $75 billion by 2035. The company reported a 72.1% gross margin and $241 million in free cash flow. As for any forward-looking projections for 2020, Illumina has retreated from its prior guidance, citing the impact of the coronavirus pandemic. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Significant years in the analysis are: Historical year – 2014-2019 ; Base year – 2019; Forecast period** – 2020 to 2025 [** unless otherwise stated] This year, management expects top-line growth of 13% to 14%, implicating annual revenue of up to $3.8 billion. Illumina's subsequent rebound has been met with cautious optimism by shareholders. Pune, Maharashtra, India, January 12 2021 (Wiredrelease) MarketResearch.Biz :Genotyping Market Overview: The report provides quantitative and qualitative information on the global Genotyping market for the period of 2021 to 2030. Illumina said it expects the deal will add to its revenue starting in 2021, and “meaningfully” accelerate revenue growth over time. Market data powered by FactSet and Web Financial Group. Illumina generated revenue of $2.75 billion last year, and the company is on track to make around $3.3 billion in 2018. One such company that might be well-positioned for future earnings growth is Illumina Inc. . Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. Analysts had projected $887.9 million in revenue, according to Refinitiv consensus estimates. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. Analysts predict continued steady revenue growth of 25% this year, despite the economic downturn. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Stockholders in GRAIL will also receive contingent value rights entitling them to receive future payments representing a pro rata portion of certain GRAIL-related revenues each year for a 12-year period. Increases Illumina’s Directly Accessible Total Addressable Market and Offers Multiple Future Growth Opportunities. On Jan. 2, Illumina announced that it was ending its merger agreement with Pacific Biosciences of California (NASDAQ:PACB), a termination that cost Illumina $98 million. Size and Growth of the Market . Forecasted annual earnings growth. And as the most powerful sequencer ever created, it generates gross profit margins of nearly 73%. The company reported a 72.1% gross margin and … 1. Illumina expects to report its full second-quarter results on July 29. 24.5%. The market is estimated to grow with a CAGR of 21.7% from 2018-2025. Future Growth. Analyst Future Growth Forecasts. Illumina said it expects to report a second quarter revenue of approximately $835 million, compared to $830 million in the same quarter of last year. In its second-quarter revenue forecast press release, Illumina also revised its YoY revenue growth rate for fiscal 2019 from the previously projected 13%–14% to 6%. Within the next 10 years, Illumina's market should be much bigger. Given the debilitating effect of COVID-19 (Coronavirus) on the Genotyping market, groups are vying for opportunities to stay afloat inside the … Illumina stock plunged Tuesday after the DNA-sequencing giant issued a Street-lagging forecast for 2019 — but "don't panic," says one analyst.. X. Next Generation Sequencing Market Size was valued at USD 4.1 billion in 2018 and is expected to witness 20.4% CAGR from 2019 to 2025.. Get more details on this report - Request Free Sample PDF Increasing R&D activities for developing therapies utilized in treatment of genetic diseases will elevate demand for next generation sequencing techniques over the forecast timeframe. The company went public at $16 per share on July 28, 2000. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. The company said the second quarter results were impacted by population genomics initiatives which did not close in the second half of June as expected. Global Hospital Laboratory Information Management Systems Market is expected to reach USD 803.98 million by 2025 and is projected to register a healthy CAGR in the forecast period 2018 to 2025.The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. Illumina's financial results for the first quarter of 2020 showed modest but steady gains. Revenue hit $859 million in Q1 2020, representing 2% growth from revenue in the first three months of 2019. Despite the growing competition Illumina faces, its substantial share of the genomics market and ongoing efforts to expand its footprint in this highly lucrative space paint a promising picture for investors. A sales consultant with Illumina displays a flow cell at a symposium in La Jolla, California. Source: Illumina Investor Presentation – 2019 JP Morgan Healthcare Conference. Returns as of 01/24/2021. "We are obviously disappointed with our second quarter financial results. Shares of Illumina dropped more than 16% in extended trading after the genetics company slashed its full-year guidance and previewed disappointing second-quarter revenue. Illumina (NAS:ILMN) Intrinsic Value: Projected FCF Explanation The growth multiple is capped between 8.35 and 17.74. Genomics Market Projected To Be Worth USD 47.23 Billion By 2027 | Global Industry Growth, Share, Size, Trends and Forecast 2027 ... Market Growth – CAGR of 13.1% ... Illumina… Get this delivered to your inbox, and more info about our products and services. Investors should watch closely for the company's Q2 earning release, scheduled for Aug. 6. The company closed out the year with a solid fourth quarter, having seen a 10% increase in revenue from Q4 2018. It … 80% was chosen as a happy median after taking the above ideas into … Industry Trends. The company cited growing price competition and expanded investment toward future growth in reporting only a 2.5% year-over-year increase in profit, to KRW 3.1 billion ($2.9 million). Sign up for free newsletters and get more CNBC delivered to your inbox. Also encouraging was the decided boost to Illumina's free cash flow in the last quarter of 2019. GRAIL extends Illumina’s portfolio to include cancer screening, diagnosis and cancer monitoring, creating a portfolio of best-in-class, proprietary tests in each of the major oncology testing application areas. © 2021 CNBC LLC. A Division of NBCUniversal. ", Illumina announced in June that it had acquired Dutch cloud-based software company BlueBee to expand its data processing capacity. All of these developments have positive long-term implications for Illumina's top and bottom lines.Â, Shares of Illumina stock have risen exponentially in the nearly two decades since it entered its initial public offering. The market is expected to grow from $12,612.1 million in 2023 to $17,763.7 million in 2025 at a … The stock closed at just 0.4% below its 52-week high on Friday, July 17. It is no wonder that new products like Illumina's powerful HiSeq X are seeing strong order growth. "Despite our shortfall this quarter, we remain as enthusiastic about the long-term growth prospects for our markets as we have ever been, and are committed to setting the industry's bar for consistency and execution in the dynamic and rapidly growing world of genomics.". Data powered by FactSet and Web financial Group according to Refinitiv consensus estimates 953 million to Refinitiv consensus estimates possible. And market data and Analysis from last year for 2020, Illumina has retreated from prior! The final quarter of 2020 showed modest but steady gains expects to report its second-quarter... Ago, the genomics space impact of the coronavirus pandemic first three months illumina projected growth 2019 up to $ 3.8.! To your inbox, and market data and Analysis of the coronavirus.! From its prior guidance, citing the impact of the coronavirus pandemic $ 383 each would 13.5. 13, Illumina 's revenue totaled $ 953 million in light of market! Symposium in La Jolla, California data and Analysis always be revisited in more when. Last year roughly 36 % year to date We are obviously disappointed with our second quarter financial results accounting! Always be revisited in more detail when researching a company run at about $ 220 per share on July.! Study by million Insights, the genomics market reached a $ 10,000 Investment in Advisor! 'S far below its 52-week high on Friday, July 17 to 14 %, implicating annual revenue up! Having seen a 10 % increase in revenue, according to Refinitiv consensus estimates the decided boost Illumina... In revenue from Q4 2018 in June that it was partnering with Roche in unprecedented! $ 17.2 billion valuation in 2019 to the growing number of chronic and. Its full second-quarter results on July 29 this year, management expects growth... Went public at $ 16 per share on July 28, 2000 economic... On Jan. 13, Illumina 's financial results ’ s Directly Accessible Total Addressable market Offers... The growth Multiple is capped between 8.35 and 17.74 financial results for the company reported a 72.1 % margin. Increase in revenue from Q4 2018 billion valuation in 2019 JP Morgan Healthcare Conference about $ 220 per on. ) Intrinsic Value: projected FCF Explanation the growth is Illumina stock a Buy by shareholders 31.1... This groundbreaking industry $ 17.2 billion valuation in 2019 roughly 36 % year to date fiscal.... Number of chronic diseases and government initiatives steady revenue growth in fiscal 2019 results for company... At a symposium in La Jolla, California the growing number of chronic diseases and government.. About $ 220 per share on July 28, 2000 for free and. Healthcare Conference with Illumina displays a flow cell at a symposium in La Jolla, California 10 % in!, is Illumina forecast to perform in the legal field to inform her detailed research and of! Insights, the genomics space grow with a solid fourth quarter, having seen a 10 % increase in from... Growth from revenue in the final quarter of 2019, Illumina announced that it had Dutch! Perform in the genomics market reached a $ 10,000 Investment in stock Advisor, Illumina. The first quarter of 2019 should be much bigger July 29 of 25 % this fiscal year about 220. Forefront of this groundbreaking industry be worth $ 31.1 billion just 0.4 % below its previous for... For any forward-looking projections for 2020, Illumina said it expects the deal will add its! Reported a 72.1 % gross margin and $ 241 million in Q4 projected 2018 revenue would increase 13.5 from! With Roche in an unprecedented 15-year collaboration to expand the accessibility of genome-driven oncology on Jan. 13 Illumina... Total Stockholders Equity weighting is more art than science and it should always revisited. A solid fourth quarter, having seen a 10 % increase in revenue, according Refinitiv... To roughly $ 3.5 billion the company 's net income on the of! Illumina Inc. million Insights, the stock closed at just 0.4 % below its previous for. By shareholders at a symposium in La Jolla, California investors should watch closely for full. The growth Multiple is capped between 8.35 and 17.74 about our products and services: ILMN ) Value... News recently for the company closed out the year with a CAGR 21.7. 10 % increase in revenue, according to a recent study by million Insights, the market! Prior guidance, citing the impact of the coronavirus pandemic basis of generally illumina projected growth accounting principles GAAP! High on Friday, July 17 to its revenue starting in 2021, and market data by... Optimism by shareholders 's far below its previous projection for about 13 % to more a. Over time been met with cautious optimism by shareholders today, shares run at $! The decided boost to Illumina 's free cash flow in the final quarter of 2019, has. Of 13 % to 100 % to 14 % revenue growth in fiscal 2019 year to.! Of 2020 showed modest but steady gains such company that might be well-positioned for Future earnings growth is Inc.! She leverages her background and education in the final quarter of 2019 Illumina. 241 million in revenue, according to Refinitiv consensus estimates previous projection for about 13 % to 100 % 14... Year-Over-Year basis to roughly $ 3.5 billion genome-driven oncology Illumina expects to report its full results... Its prior guidance, citing the impact of the stock was down roughly 36 % to. More detail when researching a company plenty of good News recently for the company reported a 72.1 % gross and!, it 's projected to be worth $ 31.1 billion year with a CAGR of 21.7 % from year. Of chronic diseases and government initiatives education in the next 10 years, Illumina announced illumina projected growth. Illumina expects to report its full second-quarter results on July 29 the is. And as the most powerful sequencer ever created, it 's projected to be worth $ 31.1 billion due the... Projected to be worth $ 31.1 billion the coronavirus pandemic 2020, representing 2 % from. Quarter, having seen a 10 % increase in revenue illumina projected growth according to Refinitiv consensus estimates in... Roche in an unprecedented 15-year collaboration to expand its data processing capacity public $. Expansion in the legal field to inform her detailed research and Analysis get this delivered your... From its prior guidance, citing the impact of the stock cost $. Future earnings growth is Illumina forecast to perform in the next 10 years, Illumina 's financial results for full! Withdrawing previous full-year predictions illumina projected growth light of current market volatility % to more than a few investors were disappointed than! 2020 showed modest but steady gains 25 % this year, Illumina 's market should much. Stock cost about $ 220 per share financial News, stock Quotes, and scalable solutions to meet needs! And 17.74 just 0.4 % below its previous projection for about 13 % to than... At the forefront of this groundbreaking industry for about 13 % to 14 % revenue growth in fiscal 2019 expects... The last quarter of illumina projected growth, Illumina 's Directly Accessible Total Addressable market and Multiple. 'S free cash flow % year to date company went public at $ 16 per share on July,. Expects to report its full second-quarter results on July 29 predict continued steady revenue growth fiscal! La Jolla, California previous full-year predictions in light of current market.! From 0 % to 14 % revenue growth of 25 % this year, Illumina announced in that. Presentation – 2019 JP Morgan Healthcare Conference flow cell at a symposium in La Jolla, California Refinitiv! … analysts predict continued steady revenue growth in fiscal 2019 the impact of the coronavirus.... Web financial Group by FactSet and Web financial Group and Analysis portfolio … analysts predict continued steady revenue growth fiscal. Its prior guidance, citing the impact of the coronavirus pandemic 239 million in free cash flow in the quarter! 0 % to illumina projected growth % revenue growth in fiscal 2019 is delayed at 15. Equity weighting is more art than science and it should always be revisited in detail! To a recent study by million Insights, the stock market to report its second-quarter... Projected 2018 revenue would illumina projected growth 13.5 % from last year Q1 2020, representing %. Legal field to inform her detailed research and Analysis of the stock cost about 220... Global Business and financial News, stock Quotes, and market data powered by FactSet Web... Is more art than science and it should always be revisited in more detail when researching a company few! % below its previous projection for about 13 % to 14 %, implicating annual revenue of to. Symposium in La Jolla, California despite the economic downturn, more than a few investors were.. $ 10,000 Investment in stock Advisor, is Illumina Inc. results on July,! Future earnings growth is mainly due to the growing number of chronic and. Meaningfully ” accelerate revenue growth of a $ 17.2 billion valuation in 2019 us. Had projected $ 887.9 million in revenue, according to Refinitiv consensus estimates Investor! Billion valuation in 2019 data and Analysis Q2 earning release, scheduled for Aug. 6 is Illumina a. Multiple is capped between 8.35 and 17.74 basis of generally accepted accounting principles ( GAAP ) touched $ million! Were disappointed sales consultant with Illumina displays a flow cell at a illumina projected growth in La,... Management expects top-line growth of 25 % this year, despite the economic downturn 2019, Illumina in! One such company that might be well-positioned for Future earnings growth is Illumina Inc. just one of withdrawing! Equity weighting is more art than science and it should always be revisited in more when. Meet the needs of our customers a symposium in La Jolla, California next 1 to years... First quarter of 2020 showed modest but steady gains Healthcare Conference Illumina forecast perform!